Press Releases

Generated third quarter revenue of $12.9 million, driven by expanded commercial organization and increasing market penetration Revised 2026 revenue guidance to $46 million to $48 million Centers for Medicare & Medicaid Services finalized policies that expand favorable reimbursement for procedures
November 10, 2026
WESTMINSTER, Colo. --(BUSINESS WIRE)--Sep. 22, 2026-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform treatment for patients with solid
September 22, 2026

Subscribe to Email Alerts

Get news delivered directly to your in box